MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

How CareDx Is Bringing AI to Transplant Care

Graphic By Amanda Pedersen, News Editor, MD+DI How CareDx Is Bringing AI to Transplant Care
CareDx has partnered with Cibiltech to commercialize Predigraft, a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss.
CareDx has partnered with Cibiltech, a French company that develops AI-based products for predictive medicine, to bring a new data analysis tool to the U.S. transplant market.

Brisbane, CA-based CareDx has partnered with Cibiltech, a French company that develops artificial intelligence-based products for predictive medicine, to commercialize Predigraft. 

Predigraft is a data analysis tool designed to provide an early prediction of a patient's risk of allograft rejection and transplant loss. It was developed from Cibiltech’s software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients.

The deal is yet another example of how AI is disrupting the status quo in medtech. MD+DI recently published this guide characterizing the current state of AI in the industry from technical considerations to regulatory and reimbursement challenges.

CareDx now has the exclusive rights to sell Predigraft in the United States. The company also acquired a minority equity ownership of Cibiltech. The companies have also agreed to collaborate to advance the development of AI in transplant care. Financial terms of the deal were not disclosed. 

The news comes on the heels of the company's recent $16 million acquisition of OTTR Complete Transplant Management, a provider of organ transplant patient tracking software. That deal is expected to close this month.

"We're moving from proprietary biomarkers to multimodality testing and then we're adding to this multimodality testing our artificial intelligence component to make sure there's digital healthcare available to transplant patients," CareDx CEO Peter Maag told MD+DI. "And this is really where we're taking our platform to make sure that patients have more information and more access to being able to monitor them over the long term of the transplantation's life."

CareDx and Cibiltech will offer demonstrations of iBox at the American Transplant Congress June 1-4, 2019 in Boston.  

“CareDx has taken another step towards bringing big data solutions to transplant patients,” Maag said. “With OTTR providing data infrastructure and with iBox providing prognostic information, we are beginning to assemble new and important solutions for caregivers that are based on artificial intelligence.”

“We are delighted to collaborate with CareDx as it is a very promising step to bring years of work on artificial intelligence from the Paris Transplant Group to transplant patients," said Alexandre Loupy, MD, iBox inventor and Cibiltech founding partner.

"Alexandre Loupy is really the world-renowned resource in artificial intelligence in transplantation," Maag said. "He has put together an incredible team, which was built from the Paris Transplant Group ... Alexandre Loupy is really a key force in artificial intelligence for transplant."

Earlier this year CareDx filed a patent infringement suit against Natera in the U.S. District Court for Delaware. The company said it is asserting U.S. Patent Nos. 9,845,497 and 8,703,652 were exclusively licensed to CareDx from Stanford University.

TAGS: News
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.